Vertex Pharmaceuticals Incorporated (VRTX)
Automate Your Wheel Strategy on VRTX
With Tiblio's Option Bot, you can configure your own wheel strategy including VRTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VRTX
- Rev/Share 45.8658
- Book/Share 67.7574
- PB 4.3302
- Debt/Equity 0.0738
- CurrentRatio 2.3618
- ROIC 0.1618
- MktCap 108089527572.0
- FreeCF/Share 13.0563
- PFCF 32.3893
- PE 29.2941
- Debt/Assets 0.0738
- DivYield 0
- ROE 0.1962
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | VRTX | Leerink Partners | Market Perform | Outperform | -- | $456 | Sept. 25, 2025 |
| Initiation | VRTX | Raymond James | -- | Market Perform | -- | -- | Sept. 3, 2025 |
| Upgrade | VRTX | Wells Fargo | Equal Weight | Overweight | -- | $460 | Aug. 6, 2025 |
| Downgrade | VRTX | Wolfe Research | Outperform | Peer Perform | -- | -- | May 7, 2025 |
| Downgrade | VRTX | Leerink Partners | Outperform | Market Perform | -- | $503 | May 6, 2025 |
| Resumed | VRTX | Cantor Fitzgerald | -- | Overweight | -- | $535 | April 22, 2025 |
| Upgrade | VRTX | Canaccord Genuity | Sell | Hold | $408 | $424 | Feb. 12, 2025 |
| Upgrade | VRTX | Canaccord Genuity | Sell | Hold | -- | -- | Feb. 11, 2025 |
| Downgrade | VRTX | Wells Fargo | Overweight | Equal Weight | -- | $460 | Jan. 30, 2025 |
| Reiterated | VRTX | H.C. Wainwright | -- | Buy | $600 | $535 | Dec. 20, 2024 |
News
Vertex Pharmaceuticals Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - VRTX
Published: February 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.
Read More
Calls of the Day: Charles Schwab, Vertex Pharma and Transocean
Published: February 11, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the latest Calls of the Day.
Read More
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Vertex reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Trikafta/Kaftrio drive year-over-year sales.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) Q4 2024 Earnings Call Transcript
Published: February 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Q4 2024 Earnings Conference Call February 10, 2025 4:30 PM ET Company Participants Susie Lisa - Senior Vice President, Investor Relations Reshma Kewalramani - President and Chief Executive Office Stuart Arbuckle - Chief Operating Officer Charlie Wagner - Chief Financial Officer Conference Call Participants Salveen Richter - Goldman Sachs Evan Seigerman - BMO Capital Markets Jessica Fye - JPMorgan Geoff Meacham - Citibank Michael Yee - Jefferies William Pickering - Bernstein Liisa Bayko - Evercore ISI Phil Nadeau - TD Cowen Eliana Merle - UBS Tazeen Ahmad - Bank of America Dave Risinger - Leerink …
Read More
Markets Steady, Positive; Q4 Earnings Keep Rolling
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
Indexes mostly shrugged off +25% steel tariffs announced by President Trump; VRTX, LSCC report for Q4.
Read More
Vertex's Revenue Surges but EPS Slips
Published: February 10, 2025 by: The Motley Fool
Sentiment: Positive
Vertex Pharmaceuticals (VRTX 0.14%), known for its innovative treatments, reported its fourth-quarter earnings on Feb. 10. The company's revenue increased significantly to $2.91 billion, which was above analysts' expectations of $2.78 billion.
Read More
Vertex Pharmaceuticals' Revenue Forecast Tops Expectations
Published: February 10, 2025 by: Investopedia
Sentiment: Positive
Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts' expectations.
Read More
Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.
Read More
About Vertex Pharmaceuticals Incorporated (VRTX)
- IPO Date 1991-07-24
- Website https://www.vrtx.com
- Industry Biotechnology
- CEO Reshma Kewalramani FASN,
- Employees 6100